Introduction
Methods
Search strategy and selection criteria
Inclusion and exclusion criteria
Quality assessment
Data extraction
Statistical analysis
Results
Eligible studies
Study | Year | Age (median) | Assay kit | No. of patients | Method | CD44V6 cut-off | CD44V6 positive | CD44V6 negative | ||
---|---|---|---|---|---|---|---|---|---|---|
Metastasis | Total | Metastasis | Total | |||||||
Deng et al. | 2013 | 18.3 | ZSGB-BIO | 90 | IHC | >6 score | 38 | 59 | 12 | 31 |
Guo et al. | 2007 | 18.6 | ZSGB-BIO | 49 | IHC | >5 % | 16 | 27 | 5 | 22 |
Hu et al. | 2009 | 19 | Santa Cruz | 87 | IHC | >3 score | 25 | 45 | 12 | 42 |
Kim et al. | 2002 | 17 | Zymed | 50 | IHC | >50 % | 4 | 26 | 6 | 24 |
Kuryu et al. | 1999 | 19 | R&D | 39 | IHC | >10 % | 13 | 18 | 10 | 21 |
Li et al. | 2008 | 23.3 | Maixin | 35 | IHC | >0 % | 14 | 19 | 3 | 16 |
Zhu et al. | 2014 | 25 | ZSGB-BIO | 66 | IHC | >1 score | 39 | 56 | 5 | 10 |
Study | Year | Age (median) | Assay kit | No. of patients | Method | CD44V6 cut-off | CD44V6 positive | CD44V6 negative | ||
---|---|---|---|---|---|---|---|---|---|---|
Metastasis | Total | Metastasis | Total | |||||||
Deng et al. | 2013 | 18.3 | ZSGB-BIO | 90 | IHC | >6 score | 56 | 59 | 20 | 31 |
Kuryu et al. | 1999 | 19 | R&D | 39 | IHC | >10 % | 14 | 18 | 9 | 21 |
Lin et al. | 2002 | 22 | Maixin | 70 | IHC | >2 score | 58 | 64 | 4 | 6 |
Zhu et al. | 2014 | 25 | ZSGB-BIO | 66 | IHC | >1 score | 53 | 56 | 6 | 10 |